ArticleMedicine2026
Elevated monocyte-lymphocyte ratio as an independent predictor of all-cause and cardiovascular mortality in hypertensive patients: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The monocyte-to-lymphocyte ratio (MLR) has been proposed as a promising inflammatory biomarker, with potential implications for cardiovascular prognosis. However, its association with mortality in hypertensive patients remains unclear. This study aimed to investigate the correlation between MLR and all-cause and cardiovascular mortality in this population. We included 15,871 hypertensive patients from the National Health and Nutrition Examination Survey (2003-2010), with external validation using National Health and Nutrition Examination Survey (2011-2018) data. Mortality details were obtained from the National Death Index. Weighted multivariable Cox regression evaluated the independent association between MLR and mortality risk; restricted cubic spline analysis visualized the relationship, and receiver operating characteristic curves assessed predictive performance. Over a median follow-up of 141 months, 2999 all-cause deaths (18.9%) and 956 cardiovascular deaths (6.0%) occurred. Using an MLR threshold of 0.39, participants were stratified into higher (>0.39) and lower (≤0.39) groups. Fully adjusted models showed that elevated MLR significantly increased all-cause mortality risk (hazard ratio = 1.42, 95% confidence interval: 1.29-1.50, P < .0001) and cardiovascular mortality risk (hazard ratio = 1.59, 95% confidence interval: 1.36-1.80, P < .0001). Restricted cubic spline revealed a U-shaped association (P < .05). External validation confirmed that higher MLR correlated with increased mortality. The area under the curve for 1-, 3-, 5-, and 10-year survival was 0.73, 0.69, 0.67, and 0.66 for all-cause mortality and 0.70, 0.69, 0.71, and 0.68 for cardiovascular mortality, respectively. Elevated MLR is independently associated with higher all-cause and cardiovascular mortality risks in hypertensive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.